Omnicell, Inc. (OMCL) Cash Flow Statement

The consistently high OCF-to-net-income ratio suggests reported net income is depressed by non-cash items such as D&A of roughly $18M to $23M and SBC of $9M to $12M per quarter. Quarters with negative net income still generated positive operating cash flow of $30M to $55M, which appears to reflect this structural gap rather than operational improvement. Investors should monitor whether this divergence narrows as amortization from prior acquisitions declines, since the current pattern warrants further investigation into the durability of the cash conversion.

The sharp sequential decline in FCF margin appears driven more by working capital swings than by any change in capital intensity, since CapEx stayed in a relatively narrow 3% to 5.5% of revenue band. The trajectory suggests cash generation is lumpy and dependent on collection timing, which may indicate limited visibility into the sustainability of recent peak FCF levels. Investors should monitor whether the 2026Q3 margin reflects normalization or a temporary working capital build.

Large working capital outflows in 2024Q3 and 2025Q3 coincided with depressed operating cash flow, suggesting receivables or inventory build-up absorbed significant cash during those periods. The reversal pattern in subsequent quarters may indicate collection timing rather than structural deterioration, though the data does not disclose receivable aging or inventory composition. Further investigation into these components would be needed to assess whether the swings reflect hospital payment cycles or implementation-timing effects tied to revenue recognition.

The absence of dividends alongside episodic buybacks suggests management has prioritized balance sheet flexibility and reinvestment over shareholder distributions. The $61.9M repurchase in 2025Q3 is large relative to that quarter's $18.5M FCF, which may indicate funding from balance sheet resources rather than current cash generation. This pattern warrants monitoring to determine whether repurchases are opportunistic responses to valuation or a shift toward a more consistent return framework.